A recent study showed that oncogenic EGFR mutations directly up-regulated PD-L1 protein expression on the surface of cells in NSCLC, and exposure to gefitinib also lead to PD-L1 up-regulation17. This evidence concerns the gene EGFR and non-small cell lung carcinoma.